www.nuvobio.com

The formation of Nuovo Biologics represents several years of research and development exploring new broad spectrum antiviral, as well as oncology, technologies. Founded in 2010 and based in Florida, the Company is commercializing an innovative set of protein drugs. Our first drug formulation is “PVX”, which appears to treat a broad spectrum of viral infections, including those caused by herpes, influenza, and particular retroviruses; another, “MMX”, for specific malignant tumors. Both drugs are expected to be effective across animal species, and possibly, in humans. Nuovo Biologics is dedicated to the research and development of the most innovative, safe and efficacious drugs and biologicals to best support, and maximize the health and wellness of human and animals.

NovoBiotic Pharmaceuticals is a privately held, early stage biotechnology company focused on the discovery and development of new drugs from natural sources. The leader in antimicrobial discovery from natural products. We focus on the discovery of new antibiotics targeting serious drug-resistant infections.

We are focused on developing novel oncology therapeutic agents for the most difficult-to-treat cancers, specifically targeting indications for which conventional therapies have failed. Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.

neoX is a biotech company that combines artificial intelligence (AI) with biophysics for drug research and development. neoX focuses on the research and development of macromolecular drugs and multispecific drugs, especially in the field of immuno-oncology. It has developed a sophisticated platform for early discovery of therapeutics by characterizing protein-protein interactions (PPI). neoX has established cooperation with biomedical companies globally to accelerate drug R&D pipelines.

Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. NuBiyota employs a world-class group of scientists and is led by a seasoned management team with extensive management and business development experience in the healthcare industry. NuBiyota has entered a strategic collaboration with the Takeda Pharmaceutical Company for the development of NuBiyota’s Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications. NuBiyota carries out its research activities in its state-of-the-art labs in Guelph, ON, Canada and has established a GMP manufacturing site in Pearl River, NY, USA. NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications.

Launched in 2021 and located in Malvern PA, 20n Bio's mission is addressing unmet medical needs by leveraging high-throughput screening and computing to develop peptide drugs with desired biophysical, functional, and pharmacological properties.